Home Cart Sign in  
Chemical Structure| 346640-08-2 Chemical Structure| 346640-08-2

Structure of CCF642
CAS No.: 346640-08-2

Chemical Structure| 346640-08-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CCF642 is a PDI-inhibiting compound with antimyeloma activity.

Synonyms: AC1LYELL

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CCF642

CAS No. :346640-08-2
Formula : C15H10N2O4S3
M.W : 378.45
SMILES Code : O=C1N(C2=CC=C(OC)C=C2)C(S/C1=C/C3=CC=C([N+]([O-])=O)S3)=S
Synonyms :
AC1LYELL
MDL No. :MFCD01899742

Safety of CCF642

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RPMI 8226 cells 292 ±11 nM 72 hours Evaluate the toxicity of CCF642-34 on RPMI 8226 cells PMC8198550
BTZ-resistant MM1.S cells 60 ±11 nM 72 hours Evaluate the toxicity of CCF642-34 on BTZ-resistant MM1.S cells PMC8198550
MM1.S cells 118 ±21 nM (LD50) 72 hours Evaluate the toxicity of CCF642-34 on MM1.S cells PMC8198550
C2C12 myoblasts 0.1 μM, 1 μM, 3 μM, 5 μM 24 hours To evaluate the inhibitory effect of CCF642 on cisplatin-induced apoptosis in C2C12 myoblasts. Results showed CCF642 dose-dependently reduced apoptotic cell percentages (3 μM to 5.17%, 5 μM to 1.73%), downregulated apoptotic markers cleaved caspase-3 and Bax, while upregulated anti-apoptotic protein Bcl-2. PMC7944388
GSC#021 20 µM 72 hours Evaluate the effect of CCF642 on GSC#021 spheroid size, results showed CCF642 significantly reduced spheroid size PMC10147657
GSC#016 20 µM 72 hours Evaluate the effect of CCF642 on GSC#016 spheroid size, results showed CCF642 significantly reduced spheroid size PMC10147657
U251-R 1.5-3 µM 72 hours Evaluate the effect of CCF642 on U251-R cell viability, results showed CCF642 significantly reduced cell viability PMC10147657
U251-S 1.5-3 µM 72 hours Evaluate the effect of CCF642 on U251-S cell viability, results showed CCF642 significantly reduced cell viability PMC10147657
L6 rat myoblasts 3 μM, 5 μM To validate the anti-apoptotic effect of CCF642 in another muscle cell model. Results showed similar significant inhibition of cisplatin-induced apoptosis as in C2C12 cells. PMC7944388

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice YES2 cell-induced ESCC cachexia model Intraperitoneal injection 10 mg/kg 3 times per week for 4 weeks To assess the ameliorative effect of CCF642 on cachexia symptoms. Results showed CCF642 treatment significantly prevented body weight loss (P=0.003), reduced muscle wasting (increased GA muscle weight, P=0.0002), upregulated MHC protein levels while downregulating MURF1 and LC3 expression, without affecting tumor volume. Additionally, CCF642 alleviated adipose tissue loss and inflammatory responses. PMC7944388
BALB/c-nu/nu nude mice Orthotopic xenograft model Intraperitoneal injection 5 mg/kg or 10 mg/kg 3 days a week for two weeks Evaluate the effect of CCF642 nanoformulation on tumor growth, results showed CCF642 nanoformulation significantly suppressed tumor growth PMC10147657

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.64mL

0.53mL

0.26mL

13.21mL

2.64mL

1.32mL

26.42mL

5.28mL

2.64mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories